Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

BTG and Collegium Pharmaceutical to develop a modified release Asthma product

BTG : 01 October, 2006  (Company News)
BTG, the medical innovations company, announced today that it has entered into a Collaboration Agreement with Collegium Pharmaceutical, Inc., a specialty product development company, to develop CP-141, a novel modified oral formulation of a product used for the treatment of asthma.
The active ingredient in the formulation is currently available in the US and is widely prescribed for the treatment of asthma for children and adults. Collegium will employ its expertise in formulation technologies to develop a product that meets the clinical needs of patients with asthma that have difficulty taking the currently available formulations. There are a large number of asthma patients that are not compliant with the available treatment options due to frequency of dosing or ease of use issues such as inability to swallow pills. The intent of this programme is to develop a flexible, extended release dosage form that will address the needs of these patient populations and in turn increase the compliance rates and overall treatment efficacy. The Collaboration Agreement provides for a development programme that will be co-funded by BTG and Collegium, as well as revenue sharing arrangement between the parties.

Thomas Logan PhD, Vice President, Drug Repositioning, commented: “The development of a modified formulation version of this asthma drug has the potential to benefit a large and currently underserved patient population by addressing a well known compliance issue. We’re very pleased to be working on this with Collegium Pharmaceutical, a strategic partner for BTG as we continue to expand our drug development portfolio.”

Michael Heffernan RPh, President of Collegium, added: “The addition of an asthma product to our ongoing sleep apnoea collaboration with BTG reflects the positive working relationship and synergy between our organisations. Both projects allow us to capitalise on the strengths of each organisation.”

Approximately 17.3 million Americans have asthma. The prevalence of asthma in the general population is 5%, and it has increased 40% in the past decade. Asthma accounts for more school absences and more hospitalisations than any other chronic illness. In most children’s hospitals in the US, it is the most common diagnosis at admission.

This announcement follows one in September 2004 regarding a Collaboration Agreement between the parties to develop a novel drug combination for the treatment of sleep apnoea. Sleep apnoea is a serious respiratory disorder that involves cessation of breathing for prolonged intervals during sleep.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 NewMaterials.com
Netgains Logo